Ovarian Cancer

  • Author: Maurie Markman, MD (More Info)
  • Associate Editor: Robert F. Ozols, MD, PhD
  • Editor In Chief: Ramaswamy Govindan, MD
  • Last Reviewed: 6/26/18 (What's New)

Summary

  • PARP is a family of enzymes critical for DNA repair with overexpression in BRCA-mutated and BRCA-like solid tumors[O’Sullivan 2014]
  • BRCA1/2 mutation status is a prognostic marker for treatment with PARP inhibitors
    • Patients with BRCA1/2 mutations have improved outcomes and longer survival
  • Germline and Somatic Mutation Testing in Patients With Ovarian Cancer
      Olaparib
        Rucaparib
          Niraparib

          Action required